E. NWANNA: Open Payments
NPI 1073746566 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,267 in 12 payments from 10 companies in 2025. Trend: 2023 $1,801 · 2024 $1,768 · 2025 $1,267
Food & beverage: $1,267
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 2 | $209 |
| Corcept Therapeutics | 2 | $206 |
| Abbott Laboratories | 1 | $146 |
| Amgen Inc. | 1 | $138 |
| AstraZeneca Pharmaceuticals LP | 1 | $134 |
| ABIOMED | 1 | $126 |
| Xeris Pharmaceuticals, Inc. | 1 | $107 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $96 |
| Eisai Inc. | 1 | $84 |
| Chiesi USA, Inc. | 1 | $22 |
Products named: Korlym, PROCLAIM, AIRSUPRA, Livdelzi, RECORLEV, JOURNAVX, Epclusa, Leqembi.
Industry payments across TX — which companies pay providers there.
